Table 1.

Immunohistochemical Staining of Melanocytic Lesions with Anti-MAP-2 Antibody

Lesion	MAP-2 staining intensity
	n	+++	++	+	−
Nevi	10	6 (60%)	0 (0%)	1 (10%)	3 (30%)
Primary melanoma	9	3 (33.3%)	1 (11.1%)	2 (22.2%)	3 (33.3%)
Metastatic melanoma	42	2 (5%)	8 (19%)	14 (33%)	18 (43%)

The relative intensity of staining of paraffin embedded tissue section with mAb M13 is shown as: no detectable immunoreactivity (−), or increasing intensity of reactivity (+, ++, and +++). n, number of specimens tested. Data are shown as the number of specimens positive or negative for MAP-2 staining (numbers in parentheses are percent total specimens). Nevi include both congenital and acquired types; primary melanomas include 2 desmoplastic specimens and 7 conventional melanomas, and metastatic melanomas include 26 lesions from lymph nodes, 13 from brains and 3 other anatomical sites (one lesion each from lung, bone, and parotid gland). Analysis of the data using Fisher’s exact test (r × c contingency table) showed strong association between intensity of MAP-2 staining and the characteristics of the melanocytic lesions studied (P = 0.0039).